Maravai LifeSciences Holdings, Inc. (MRVI)

Market Cap	681.21M
Revenue (ttm)	241.86M
Net Income (ttm)	-162.71M
Shares Out	254.66M
EPS (ttm)	-1.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	912,245
Open	2.710
Previous Close	2.730
Day's Range	2.630 - 2.770
52-Week Range	1.665 - 10.030
Beta	0.28
Analysts	Hold
Price Target	6.84 (+155.7%)
Earnings Date	Aug 6, 2025

About MRVI

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 20, 2020
• Employees: 570
• Stock Exchange: NASDAQ
• Ticker Symbol: MRVI
• Website: https://www.maravai.com

Financial Performance

In 2024, MRVI's revenue was $259.19 million, a decrease of -10.30% compared to the previous year's $288.95 million. Losses were -$144.85 million, 21.7% more than in 2023.

Analyst Summary

According to 10 analysts, the average rating for MRVI stock is "Hold." The 12-month stock price target is $6.84, which is an increase of 155.70% from the latest price.

Price Target

$6.84

(155.70% upside)

Analyst Consensus: Hold